VANCOUVER, BC – TheNewswire - June 1, 2021 - AREV NANOTEC BRANDS INC. (CSE:AREV); (CNSX:AREV.CN); (OTC:AREVF) (”AREV” or the “Company”) Is pleased to announce it has expanded its extraction results to Clinical Characterization of Compounds and provides this update of corporate developments consistent with its news announcements and AREV’s transformed corporate website now located at www.arevlifesciences.com.  The Company encourages its shareholders and interested parties to review the new website in light of this and recent news releases.

In the first five months of 2021, AREV has advanced its core competencies in extraction systems, functional ingredient production, and natural product formulations, expanding its know-how into innovative plant compound identification and medicinal characterization for utility in the Company’s development of advanced-stage nutritional foods and discovery of plant-based drugs (or phytomedicinalization).  Working with noted experts recruited to AREV’s leadership and Scientific Advisory Board (SAB), AREV’s corporate team has also initiated collaborations and significant negotiations with third-party academic and business partners to enhance its participation in programs involving preclinical, clinical, and U.S. FDA-approved drugs.

Mike Withrow, AREV CEO, said, “AREV is becoming a fully integrated early-stage life sciences enterprise.  I am pleased that AREV’s pursuit of its prior business model created the valuable shareholder opportunity on which the Company is quickly executing, from enhancement of AREV’s extraction innovations to its proprietary initiatives with the characterization of therapeutic compounds found in sea cucumber, Moringa, and other natural sources.  AREV is in a substantial growth stage through its advancement of creative collaborations with the advice of its high-level appointments to the Company’s Scientific Advisory Board.”

AREV is invested in phytomedicinal discoveries of broad spectrum antivirals and has made significant commitments to human nutrition in areas of unmet need in strategic markets, including the development of an advanced-stage Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM), branded as SUS-TAINN, and an Enteral Formula, RES-TORE. Through our SAB and our development of collaborations, with Voynich Biosciences, Inc. and Oyagen, AREV is connected to the Linus Pauling Institute at Oregon State University (OSU).  AREV is engaging scientists to characterize compounds for its proprietary ingredients while building AREV’s team of preclinical drug discovery partners in the Company’s rational drug design, driven by molecular epidemiology.

“Our strategy is dedicated to generating revenue to support drug development both through novel therapeutic approaches to human nutrition in contexts of malnutrition and pandemic disease and through development of enhanced OTC products with validated claims developed with advanced, scientifically-characterized ingredients,” said Roscoe M. Moore, Jr., DVM, MPH, PHD, Assistant U.S. Surgeon General (retired), Chairman of AREV’s SAB.

On the second of these revenue strategies, through the recently announced collaboration with GVB Biopharma, AREV is preparing to launch two soft gel products containing proprietary, characterized ingredients derived from sea cucumber and hops infused with CBD.  

For further information, contact Mike Withrow, news@arevlifesciences.com 778-929-6536. For more information visit arevlifesciences.com.

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Brands Inc.  
AREV NanoTec Brands Inc. (CSE: AREV) (OTC: AREVF) produces phytomedicinal extracts via its proprietary state-of-the-art extraction methodologies for the life science industry. These premium ingredients are utilized in SUS-TAINN™, a Ready-To-Use Therapeutic Food (RUTF) to impact global malnutrition on Severe / Acute Malnutrition (SAM) and the Enteral Formula markets. The AREV model is to advance extraction technologies that provide opportunities for next generation phytomedicine.  AREV Nanotec is a member of BIO, the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other countries.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.